Vagus Nerve Stimulation Market

Vagus nerve stimulation (VNS) therapy is designed to avoid seizures by sending consistent, mild pulses of electrical signals to the brain through the vagus nerve. These pulses are delivered by a device, which resembles a pacemaker. Vagus nerve is a part of the autonomic nervous system that controls involuntary functions of the body such as heart rate. It passes through the neck, which passes between the chest and abdomen to the lower part of the brain. VNS device is referred to as the "pacemaker of the brain," and is placed under the skin on the chest wall. A wire runs from it to the vagus nerve in the neck. Vagus nerve stimulators are used in treatment of intractable epilepsy and treatment-resistant depression.

The major factors that drive the growth of global vagus nerve stimulation market are increase in prevalence of neurological disorders as migraine and epilepsy among all age groups and positive clinical outcomes regarding the use of this technique. However, dearth of skilled professionals and high cost associated with neurostimulator devices restrict the market growth. Conversely, increase in R&D activities to expand the indications for the use of neurostimulators is expected to provide lucrative growth opportunities to the market. For instance, vagus nerve stimulation is being explored for managing diseases related to organs and muscle function connected to the vagus nerve.

The report global vagus nerve stimulation market is segmented based on product, application, end user, biomaterial, and geography. On the basis of product, the market is bifurcated as implantable VNS devices and external VNS devices. By application, it is categorized into depression, epilepsy, and migraine. In terms of biomaterial, it is divided into ceramics, metallic, and polymerics. In terms of end user, it is classified into hospitals, ambulatory surgical centers (ASCS), and others. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Medtronic Plc., ElectroCore LLC, LivaNova Plc., Boston Scientific Corporation, Aleva Neurotherapeutics SA, BioControl Medical, Bioness Inc., EnteroMedics Inc., Nevro Corporation, and NeuroPace Inc.

Key Benefits

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global vagus nerve stimulation market.
• Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities across the geographies.
• This report entails the detailed quantitative analysis of the current market and estimations from 2016 to 2023 to identify the prevailing opportunities.
• Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
• Region- and country-wise market conditions are comprehensively analyzed in the report.

Vagus Nerve Stimulation Market Key Segments:

By Product

• Implantable VNS Devices
• External VNS Devices

By Application

• Depression
• Epilepsy
• Migraine

By Biomaterial

• Ceramics
• Metallic
• Polymerics

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCS)
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Venezuela
  • Saudi Arabia
  • South Africa
  • Argentina
  • Rest of LAMEA

 Vagus Nerve Stimulation Market Report Highlights